Test volume for the firm's Cologuard colorectal cancer screening test rose 49 percent year over year during the quarter.
Biomatrica's sample collection tubes ensure quality preservation of circulating tumor DNA and cells, promoting high-quality liquid biopsy results, Exact said.
Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.
The company said volumes for its Cologuard colon cancer screening test rose 59 percent to 215,000 during the quarter.
The company said it plans to use the net proceeds for general corporate purposes, including for working capital and possible acquisitions.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.
The company said test volume rose 87 percent to 186,000 during the quarter.
A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.
A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.
In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.
A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.
